Preclinical Data Highlight the Significant Antigenic Shift

– Data demonstrate sotrovimab, developed by Vir in conjunction with GlaxoSmithKline, continues to retain in vitro neutralizing activity against all tested...

Related Keywords

United States ,Australia ,Japan ,United Kingdom ,Singapore ,Saudi Arabia ,United Arab Emirates ,Canada ,Switzerland ,Great Britain , ,Glaxosmithkline ,Vir Biotechnology Inc ,Monoclonal Antibody Administration ,Xencor Inc ,European Commission ,Drug Administration ,Committee For Human Medicinal Products ,Nasdaq ,European Medicines Agency ,Delta Plus ,New England Journal ,Human Medicinal Products ,Special Approval ,Emergency Pathway ,Marketing Authorization Application ,United Arab ,Joint Procurement Agreement ,Member States ,Fact Sheets ,Fact Sheet ,Healthcare Providers ,Emergency Use Authorization ,Including Anaphylaxis ,Emergency Use ,Nasdaq Vir ,Vir Biotechnology ,Nc ,Micron ,Covid 19 ,Otrovimab ,Monoclonal Antibodies ,Eutralizing Mabs ,